These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 38455367)

  • 1. Molecular features of gastroenteropancreatic neuroendocrine carcinoma: A comparative analysis with lung neuroendocrine carcinoma and digestive adenocarcinomas.
    Zhang J; Chen H; Zhang J; Wang S; Guan Y; Gu W; Li J; Zhang X; Li J; Wang X; Lu Z; Zhou J; Peng Z; Sun Y; Shao Y; Shen L; Zhuo M; Lu M
    Chin J Cancer Res; 2024 Feb; 36(1):90-102. PubMed ID: 38455367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ctDNA in Neuroendocrine Carcinoma of Gastroenteropancreatic Origin or of Unknown Primary: The CIRCAN-NEC Pilot Study.
    Gerard L; Garcia J; Gauthier A; Lopez J; Durand A; Hervieu V; Lemelin A; Chardon L; Landel V; Gibert B; Lombard-Bohas C; Payen L; Walter T
    Neuroendocrinology; 2021; 111(10):951-964. PubMed ID: 33099543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum Biomarker Status with a Distinctive Pattern in Prognosis of Gastroenteropancreatic Neuroendocrine Carcinoma.
    Zhang J; Cao Y; Zhang P; Zhang X; Li J; Zhou J; Wang X; Peng Z; Sun Y; Li J; Shen L; Lu M
    Neuroendocrinology; 2022; 112(8):733-743. PubMed ID: 34592743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The molecular characteristics of high-grade gastroenteropancreatic neuroendocrine neoplasms.
    Venizelos A; Elvebakken H; Perren A; Nikolaienko O; Deng W; Lothe IMB; Couvelard A; Hjortland GO; Sundlöv A; Svensson J; Garresori H; Kersten C; Hofsli E; Detlefsen S; Krogh M; Sorbye H; Knappskog S
    Endocr Relat Cancer; 2021 Nov; 29(1):1-14. PubMed ID: 34647903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of KRAS and BRAF mutations on treatment efficacy and survival in high-grade gastroenteropancreatic neuroendocrine neoplasms.
    Elvebakken H; Hjortland GO; Garresori H; Andresen PA; Janssen EAM; Vintermyr OK; Lothe IMB; Sorbye H
    J Neuroendocrinol; 2023 Apr; 35(4):e13256. PubMed ID: 37017614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic Characteristics of Colorectal Neuroendocrine Carcinoma: More Similar to Colorectal Adenocarcinoma.
    Chen L; Liu M; Zhang Y; Guo Y; Chen MH; Chen J
    Clin Colorectal Cancer; 2021 Jun; 20(2):177-185.e13. PubMed ID: 33041225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma-like and Non-Small Cell Carcinoma-like Subsets.
    Rekhtman N; Pietanza MC; Hellmann MD; Naidoo J; Arora A; Won H; Halpenny DF; Wang H; Tian SK; Litvak AM; Paik PK; Drilon AE; Socci N; Poirier JT; Shen R; Berger MF; Moreira AL; Travis WD; Rudin CM; Ladanyi M
    Clin Cancer Res; 2016 Jul; 22(14):3618-29. PubMed ID: 26960398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic and immunohistochemical profiling of small cell and large cell neuroendocrine carcinomas of the breast.
    Bean GR; Najjar S; Shin SJ; Hosfield EM; Caswell-Jin JL; Urisman A; Jones KD; Chen YY; Krings G
    Mod Pathol; 2022 Oct; 35(10):1349-1361. PubMed ID: 35590107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of TP-53/Rb-1 Co-Mutation in Large Cell Neuroendocrine Carcinoma.
    Saghaeiannejad Esfahani H; Vela CM; Chauhan A
    Front Oncol; 2021; 11():653153. PubMed ID: 34141612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuroendocrine carcinoma and mixed neuroendocrine‒non-neuroendocrine neoplasm of the stomach: a clinicopathological and exome sequencing study.
    Ishida S; Akita M; Fujikura K; Komatsu M; Sawada R; Matsumoto H; Saegusa J; Itoh T; Kakeji Y; Zen Y
    Hum Pathol; 2021 Apr; 110():1-10. PubMed ID: 33359239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gastroenteropancreatic High-Grade Neuroendocrine Neoplasms: Histology and Molecular Analysis, Two Sides of the Same Coin.
    Busico A; Maisonneuve P; Prinzi N; Pusceddu S; Centonze G; Garzone G; Pellegrinelli A; Giacomelli L; Mangogna A; Paolino C; Belfiore A; Kankava K; Perrone F; Tamborini E; Pruneri G; Fazio N; Milione M
    Neuroendocrinology; 2020; 110(7-8):616-629. PubMed ID: 31557757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploring the molecular features and genetic prognostic factors of pulmonary high-grade neuroendocrine carcinomas.
    Wang H; Yan L; Zhu Y; Sun W; Yang X; Liu X; Chi K; Huang X; Zhou L; Lin D
    Hum Pathol; 2023 Dec; 142():81-89. PubMed ID: 37742943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular Characterization of Neuroendocrine Carcinomas of the Endometrium: Representation in All 4 TCGA Groups.
    Howitt BE; Dong F; Vivero M; Shah V; Lindeman N; Schoolmeester JK; Baltay M; MacConaill L; Sholl LM; Nucci MR; McCluggage WG
    Am J Surg Pathol; 2020 Nov; 44(11):1541-1548. PubMed ID: 32773531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unraveling molecular pathways of poorly differentiated neuroendocrine carcinomas of the gastroenteropancreatic system: A systematic review.
    Girardi DM; Silva ACB; Rêgo JFM; Coudry RA; Riechelmann RP
    Cancer Treat Rev; 2017 May; 56():28-35. PubMed ID: 28456055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Presence of RB1 or Absence of LRP1B Mutation Predicts Poor Overall Survival in Patients with Gastric Neuroendocrine Carcinoma and Mixed Adenoneuroendocrine Carcinoma.
    Song IH; Ahn B; Park YS; Kim DH; Hong SM
    Cancer Res Treat; 2024 Sep; ():. PubMed ID: 39327909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinicopathological and molecular profile of grade 3 gastroenteropancreatic neuroendocrine neoplasms.
    Taboada R; Claro L; Felismino T; de Jesus VH; Barros M; Riechelmann RP
    J Neuroendocrinol; 2022 Apr; 34(4):e13099. PubMed ID: 35174558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microsatellite unstable gastrointestinal neuroendocrine carcinomas: a new clinicopathologic entity.
    Sahnane N; Furlan D; Monti M; Romualdi C; Vanoli A; Vicari E; Solcia E; Capella C; Sessa F; La Rosa S
    Endocr Relat Cancer; 2015 Feb; 22(1):35-45. PubMed ID: 25465415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New model for gastroenteropancreatic large-cell neuroendocrine carcinoma: establishment of two clinically relevant cell lines.
    Krieg A; Mersch S; Boeck I; Dizdar L; Weihe E; Hilal Z; Krausch M; Möhlendick B; Topp SA; Piekorz RP; Huckenbeck W; Stoecklein NH; Anlauf M; Knoefel WT
    PLoS One; 2014; 9(2):e88713. PubMed ID: 24551139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. REST Inactivation and Coexpression of ASCL1 and POU3F4 Are Necessary for the Complete Transformation of RB1/TP53-Inactivated Lung Adenocarcinoma into Neuroendocrine Carcinoma.
    Masawa M; Sato-Yazawa H; Kashiwagi K; Ishii J; Miyata-Hiramatsu C; Iwamoto M; Kohno K; Miyazawa T; Onozaki M; Noda S; Shimizu Y; Niho S; Yazawa T
    Am J Pathol; 2022 Jun; 192(6):847-861. PubMed ID: 35367201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic factors of metastatic neuroendocrine carcinoma under first-line treatment with platinum etoposide with a focus on NEC score and Rb expression: Results from the multicentre RBNEC study of the Groupe d'Etude des Tumeurs Endocrines (GTE) and the ENDOCAN-RENATEN network.
    Hadoux J; Kanaan C; Durand A; Hescot S; Hautefeuille V; Cadiot G; Tauveron I; Laboureau S; Do Cao C; Walter T; Petorin C; Blanchet O; Jannin A; Gu C; Faron M; Leteurtre E; Rousselet MC; Zakeyh JJ; Marchal A; Chatelain D; Beaulaton C; Hervieu V; Ducreux M; Scoazec JY; Baudin E
    Eur J Cancer; 2021 Jul; 152():100-115. PubMed ID: 34090142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.